Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.

Not Applicable

Withdrawn

• Conditions: Ovarian Hyperstimulation Syndrome; Infertility Drugs; Female

• Registration Number: NCT00365027
• Lead Sponsor: HaEmek Medical Center, Israel

Brief Summary

It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-08-15
• Study First Submitted QC: 2006-08-15
• Study First Posted: 2006-08-16
• Status Verified: 2015-09
• Last Update Submitted: 2015-09-03
• Last Update Posted: 2015-09-04

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

• Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation

Exclusion Criteria

• Patient's refusal to participate

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Implantation rate per transfer
Pregnancy rate per embryo transfer
Implantation rate per IVF cycle
Pregnancy rate per IVF cycle